BURLINGAME, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team ...

BURLINGAME, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team ...

BURLINGAME, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) has received a consensus rating of “Buy” from the five analysts that are presently covering the firm, Marketbeat reports.

Detailed price information for Corvus Pharma Com (CRVS-Q) from The Globe and Mail including charting and trades.

Read Our Latest Research Report on CRVS Corvus Pharmaceuticals Stock Down 2.6 % Shares of CRVS stock opened at $5.30 on Wednesday. The firm has a market cap of $340.58 million, a PE ratio of -5.70 ...

Corvus Pharmaceuticals, Inc. (CRVS) stock price is 5.36 and Corvus Pharmaceuticals, Inc. (CRVS) 10-day simple moving average is 5.21. Corvus Pharmaceuticals, Inc. (CRVS) stock price is 5.36 and ...